Cargando…

Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy

Glioblastoma, the most common primary brain tumor in adults, is an incurable malignancy with poor short-term survival and is typically treated with radiotherapy along with temozolomide. While the development of tumor-treating fields (TTFields), electric fields with alternating low and intermediate i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Yunhui, Kim, Eun Ho, Sai, Sei, Kim, Jin Su, Cho, Jae-Min, Kim, Hyeongi, Baek, Jeong-Hwa, Kim, Jeong-Yub, Hwang, Sang-Gu, Yoon, Myonggeun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274791/ https://www.ncbi.nlm.nih.gov/pubmed/30469352 http://dx.doi.org/10.3390/ijms19113684

Ejemplares similares

Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study
por: Jo, Yunhui, et al.
Publicado: (2018)

Effectiveness of a Fractionated Therapy Scheme in Tumor Treating Fields Therapy
por: Jo, Yunhui, et al.
Publicado: (2019)

Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis
por: Kim, Eun Ho, et al.
Publicado: (2016)

Gold nanoparticles as a potent radiosensitizer in neutron therapy
por: Kim, Eun Ho, et al.
Publicado: (2017)

Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment
por: Lee, Yeon-Joo, et al.
Publicado: (2020)

5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy
por: Lee, Yeon-Joo, et al.
Publicado: (2019)

Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation
por: Kim, Eun Ho, et al.
Publicado: (2016)

Emodin coupled with high LET neutron beam—a novel approach to treat on glioblastoma
por: Kim, Jeong-Yub, et al.
Publicado: (2022)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Interaction of curcumin with glioblastoma cells via high and low linear energy transfer radiation therapy inducing radiosensitization effects
por: Kim, Jeong-Yub, et al.
Publicado: (2022)

Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib
por: Yoo, Jeong-Ju, et al.
Publicado: (2018)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
por: Kim, Hwi Young, et al.
Publicado: (2018)

Role of extracellular matrix and microenvironment in regulation of tumor growth and LAR-mediated invasion in glioblastoma
por: Kim, Yangjin, et al.
Publicado: (2018)

Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
por: Lee, Seulki, et al.
Publicado: (2018)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy
por: Jin, Chae Eun, et al.
Publicado: (2023)

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer()()
por: Choi, Kyung Hwa, et al.
Publicado: (2018)

CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
por: Chang, Young, et al.
Publicado: (2020)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway
por: Baek, Jeong-Hwa, et al.
Publicado: (2019)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

Effects of combined radiofrequency field exposure on amyloid-beta–induced cytotoxicity in HT22 mouse hippocampal neurones
por: Lee, Jong-Sun, et al.
Publicado: (2016)

Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma
por: Choi, Mun Ki, et al.
Publicado: (2011)

Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?
por: Lee, Jayoung, et al.
Publicado: (2017)

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
por: Kim, Young-Seon, et al.
Publicado: (2018)

Aripiprazole sensitizes head and neck cancer cells to ionizing radiation by enhancing the production of reactive oxygen species
por: Jeong, Hyeon‐Jeong, et al.
Publicado: (2022)

Feasibility study on the verification of actual beam delivery in a treatment room using EPID transit dosimetry
por: Baek, Tae Seong, et al.
Publicado: (2014)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
por: Cho, Yuri, et al.
Publicado: (2017)

Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
por: Choi, Na Ryung, et al.
Publicado: (2022)

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016)

Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling
por: Kim, Eun Ho, et al.
Publicado: (2022)

Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
por: Eun, Jung Woo, et al.
Publicado: (2023)

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
por: Oh, Chung Ryul, et al.
Publicado: (2019)

Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
por: Jeong, Soung Won, et al.
Publicado: (2013)

Kilovoltage radiotherapy for companion animals: dosimetric comparison of 300 kV, 450 kV, and 6 MV X-ray beams
por: Seo, Jaehyeon, et al.
Publicado: (2018)

Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
por: Kim, Yong Bae, et al.
Publicado: (2013)

Correlation of ACE2 with RAS components after Losartan treatment in light of COVID-19
por: Zaheer, Javeria, et al.
Publicado: (2021)

Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era
por: Byun, Hwa Kyung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_93f9uh80tdpqeagncscdb26hov